RSS

clinical trial

A combination of drugs has offered promising results in an early clinical trial, where it has shrunk tumours in ovarian and lung cancer patients and prevented tumour growth for nearly six months. more

News

A clinical trial has been started to evaluate and validate a urine-based point of care (POC) diagnostic from Mologic, aimed at helping cystic fibrosis (CF) patients monitor and manage their condition at home. more

Technology

A new prophylactic vaccine aimed at providing immunity against several types of HIV-1 infection has provided promising results in a Phase I/IIa clinical trial, recently published in The Lancet, of just under 400 patients. more

News

The European initiation of a Phase II clinical trial studying the effectiveness of tumour infiltrating lymphocytes (TIL) therapy in the treatment of patients with metastatic melanoma has been announced by Sarah Cannon Research Institute — UK. more

News

New innovations in drug development have a positive impact on clinical trial timelines, likelihood of market launch and inclusion on payer formularies, according to a new report released by the Economist Intelligence Unit and commissioned by PAREXEL more

News

Contract development and manufacturing organisation (CDMO), Juniper Pharma Services, has revealed its expansion into its UK-based drug development and clinical trial manufacturing facilities. more

News

The first patient has been enrolled by InterveXion in STAMPOUT — the first trial in methamphetamine users of the first-in-class anti-methamphetamine antibody IXT-m200 — the news of which Catalent Pharma Solutions has welcomed. more

News

The first European approval for a Phase II clinical trial with THN102 in Parkinson’s patients has been announced by biopharmaceutical company, Theranexus. more

News

Clinical-stage biotech company, Genoscience Pharma, has started administering GNS561 in a Phase I/IIa trial of patients with advanced liver cancer. more

News

A Phase II clinical trial has begun in the US to evaluate a new drug, GDC-0084, that targets the signalling pathway implicated in almost all (90%) of glioblastoma multiforme brain cancer cases. more

News